Human Hepatocellular Carcinoma (HCC)
Funding
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tian, G.; Yang, S.; Yuan, J.; Threapleton, D.; Zhao, Q.; Chen, F.; Cao, H.; Jiang, T.; Li, L. Comparative efficacy of treatment strategies for hepatocellular carcinoma: Systematic review and network meta-analysis. BMJ Open 2018, 8, e021269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bangaru, S.; Marrero, J.A.; Singal, A.G. Review article: New therapeutic interventions for advanced hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2019, 51, 78–89. [Google Scholar] [CrossRef] [PubMed]
- European Association for The Study of The Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, C.M.; Wang, H.J.; Keam, B.; Yu, Y.S.; Kim, J.H.; Kim, D.-S.; Bae, S.H.; Kim, G.-D.; Lee, J.K.; Seo, Y.B.; et al. Gene signature for sorafenib susceptibility in hepatocellular carcinoma: Different approach with a predictive biomarker. Liver Cancer 2020, 9, 182–192. [Google Scholar] [CrossRef] [PubMed]
- Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.-Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 2020, 382, 1894–1905. [Google Scholar] [CrossRef] [PubMed]
- Tagliamonte, M.; Mauriello, A.; Cavalluzzo, B.; Ragone, C.; Manolio, C.; Petrizzo, A.; Buonaguro, L. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. Cancer Lett. 2020, 473, 25–32. [Google Scholar] [CrossRef] [PubMed]
- Montalbano, M.; Georgiadis, J.; Masterson, A.L.; McGuire, J.T.; Prajapati, J.; Shirafkan, A.; Rastellini, C.; Cicalese, L. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma. Oncol. Rep. 2017, 37, 1291–1300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Buonaguro, L. New vaccination strategies in liver cancer. Cytokine Growth Factor Rev. 2017, 36, 125–129. [Google Scholar] [CrossRef] [PubMed]
- Buonaguro, L.; Mauriello, A.; Cavalluzzo, B.; Petrizzo, A.; Tagliamonte, M. Immunotherapy in hepatocellular carcinoma. Ann. Hepatol. 2019, 18, 291–297. [Google Scholar] [CrossRef] [PubMed]
- Kim, D.J.; Cho, J.-Y.; Yu, K.-S.; Jang, I.-J.; Yoon, J.H.; Park, T. Comprehensive metabolomic search for biomarkers to differentiate early stage hepatocellular carcinoma from cirrhosis. Cancers 2019, 11, 1497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Znati, S.; Carter, R.; Vasquez, M.; Westhorpe, A.; Shahbakhti, H.; Prince, J.; Vlckova, P.; De Vellis, C.; Bascal, Z.; Loizidou, M.; et al. Radiosensitisation of hepatocellular carcinoma cells by vandetanib. Cancers 2020, 12, 1878. [Google Scholar] [CrossRef] [PubMed]
- Xing, J.; Bhuria, V.; Bui, K.C.; Nguyen, M.L.T.; Hu, Z.; Hsieh, C.-J.; Wittstein, K.; Stadler, M.; Wilkens, L.; Li, J.; et al. Haprolid inhibits tumor growth of hepatocellular carcinoma through Rb/E2F and Akt/mTOR inhibition. Cancers 2020, 12, 615. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ogawa, E.; Nomura, H.; Nakamuta, M.; Furusyo, N.; Kajiwara, E.; Dohmen, K.; Kawano, A.; Ooho, A.; Azuma, K.; Takahashi, K.; et al. Incidence of hepatocellular carcinoma after treatment with sofosbuvir-based or sofosbuvir-free regimens in patients with chronic hepatitis C. Cancers 2020, 12, 2602. [Google Scholar] [CrossRef] [PubMed]
- Tampaki, M.; Ionas, E.; Hadziyannis, E.; Deutsch, M.; MalagariMary, K.; Koskinas, J. Association of TIM-3 with BCLC stage, serum PD-L1 detection, and response to transarterial chemoembolization in patients with hepatocellular carcinoma. Cancers 2020, 12, 212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takahashi, H.; Kawaguchi, T.; Yan, L.; Peng, X.; Qi, Q.; Morris, L.G.T.; Chan, T.A.; Tsung, A.; Otsuji, E.; Takabe, K. Immune cytolytic activity for comprehensive understanding of immune landscape in hepatocellular carcinoma. Cancers 2020, 12, 1221. [Google Scholar] [CrossRef] [PubMed]
- Pascut, D.; Pratama, M.Y.; Vo, N.V.; Masadah, R.; Tiribelli, C. The crosstalk between tumor cells and the microenvironment in hepatocellular carcinoma: The role of exosomal microRNAs and their clinical implications. Cancers 2020, 12, 823. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, Y.; Cho, Y.; Lee, J.-H.; Bin Lee, Y.; Cho, E.J.; Yu, S.J.; Sinn, D.H.; Kim, B.H.; Kim, S.H.; Yi, N.-J.; et al. Comparison of models for tumor recurrence after liver transplantation for the patients with hepatocellular carcinoma: A multicenter long-term follow-up study. Cancers 2019, 11, 1295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Buonaguro, L. Human Hepatocellular Carcinoma (HCC). Cancers 2020, 12, 3739. https://doi.org/10.3390/cancers12123739
Buonaguro L. Human Hepatocellular Carcinoma (HCC). Cancers. 2020; 12(12):3739. https://doi.org/10.3390/cancers12123739
Chicago/Turabian StyleBuonaguro, Luigi. 2020. "Human Hepatocellular Carcinoma (HCC)" Cancers 12, no. 12: 3739. https://doi.org/10.3390/cancers12123739